Phase 2 Schizophrenia Trial, Recruiting NCT05778591 Sponsor: University of California, Los Angeles Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT05778591
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 60 years of age
  • People who can understand spoken English well enough to follow the testing procedures
  • People who scored below a certain threshold on a social network questionnaire used during screening (the trial site can explain this score in more detail)
  • People who have received a formal diagnosis of schizophrenia according to current diagnostic guidelines (DSM-5)
  • People whose condition has been clinically stable — meaning no hospital stays in the past 6 months, no medication changes in the past 6 months, and no more than moderate positive symptoms currently

Who may not be able to join:

  • People with a medical history indicating an IQ below 70 or a developmental disability
  • People currently taking opioid medications
  • People with a medically significant neurological condition (such as epilepsy), heart condition (such as irregular heartbeat), or breathing condition (such as asthma), based on medical history
  • People with a history of serious head injury — for example, loss of consciousness for more than an hour, lasting cognitive effects, or rehabilitation treatment following a head injury
  • People with a substance or alcohol use disorder in the past six months, or any history of opioid use disorder
  • People who have taken sedatives or benzodiazepines within 24 hours before testing
  • People who test positive on a urine drug screen or show visible signs of intoxication on the day of assessment
  • People who are pregnant or think they may be pregnant, based on self-report and urine testing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 3107945577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
17 May 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Attention bias

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov